Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Elimination of [14C]E7090 in Healthy Males
NCT04493255Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tasurgratinib in cholangiocarcinoma (CCA) and biliary tract cancer (BTC), sponsored by Eisai Co., Ltd. Primary endpoints: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine, Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine and 9 more. Started Sep 2020; status: completed.
02
Drugs
tasurgratinib
03
Conditions
cholangiocarcinoma (CCA)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04493255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493255.